Irina Smirnow
Overview
Explore the profile of Irina Smirnow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sotiriadis S, Beil J, Berchtold S, Smirnow I, Schenk A, Lauer U
Viruses
. 2024 May;
16(5).
PMID: 38793657
NUT (nuclear-protein-in-testis) carcinoma (NC) is a highly aggressive tumor disease. Given that current treatment regimens offer a median survival of six months only, it is likely that this type of...
2.
Scheicher N, Berchtold S, Beil J, Smirnow I, Schenk A, Lauer U
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339240
Neuroendocrine neoplasms represent a heterogenous group of rare tumors whose current therapeutic options show only limited efficacy. Oncolytic viruses exert their mode of action through (onco-)lysis of infected tumor cells...
3.
Yurttas C, Beil J, Berchtold S, Smirnow I, Kloker L, Sipos B, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254857
Effective treatment options for peritoneal surface malignancies (PSMs) are scarce. Oncolytic virotherapy with recombinant vaccinia viruses might constitute a novel treatment option for PSM. We aimed to identify the most...
4.
Koch J, Beil J, Berchtold S, Monch D, Maass A, Smirnow I, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851574
Oncolytic virotherapy constitutes a promising treatment option for many solid cancers, including peritoneal carcinomatosis (PC), which still represents a terminal stage of many types of tumors. To date, the in...
5.
Ohnesorge P, Berchtold S, Beil J, Haas S, Smirnow I, Schenk A, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681742
NUT carcinoma (NC) is an extremely aggressive tumor and current treatment regimens offer patients a median survival of six months only. This article reports on the first in vitro studies...
6.
Berchtold S, Beil J, Raff C, Smirnow I, Schell M, DAlvise J, et al.
Int J Mol Sci
. 2020 Oct;
21(20).
PMID: 33076270
Genetically modified vaccinia viruses (VACVs) have been shown to possess profound oncolytic capabilities. However, tumor cell resistance to VACVs may endanger broad clinical success. Using cell mass assays, viral replication...
7.
Kloker L, Berchtold S, Smirnow I, Beil J, Krieg A, Sipos B, et al.
BMC Cancer
. 2020 Jul;
20(1):628.
PMID: 32631270
Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors...
8.
Klose C, Berchtold S, Schmidt M, Beil J, Smirnow I, Venturelli S, et al.
BMC Cancer
. 2019 Dec;
19(1):1172.
PMID: 31795974
Background: In pediatric sarcomas, outcomes of established therapies still remain poor, especially due to high-grade resistances to chemotherapeutic compounds. Taking novel biological approaches into account, virotherapy was found to be...
9.
Scheubeck G, Berchtold S, Smirnow I, Schenk A, Beil J, Lauer U
Viruses
. 2019 Jul;
11(7).
PMID: 31284426
Starvation sensitizes tumor cells to chemotherapy while protecting normal cells at the same time, a phenomenon defined as differential stress resistance. In this study, we analyzed if starvation would also...
10.
Kloker L, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B, Krieg A, et al.
Neuroendocrinology
. 2019 Jul;
109(4):346-361.
PMID: 31280274
Metastatic neuroendocrine cancer still constitutes a palliative situation, lacking promising treatment options. Oncolytic virotherapy, a novel type of virus-based immunotherapy, lyses tumor cells using genetically engineered viruses thereby activating the...